Table 2

Effectiveness of second TNF inhibitor (INF, ETA and ADA) based on ΔDAS28, % of patients with low disease activity or remission at 6 months and % of patients achieving ΔDAS28 of at least 1.2 at 6 months, stratified by disease activity at baseline (high vs no high)

No high disease activity at baselineINF
N=31
ETA
N=184
ADA
N=199
Difference between groups (p value)Post hoc comparisons between groups
DAS28 baseline4.0±0.8
(31)
4.0±0.9
(184)
3.8±1.0
(199)
0.12
DAS28 6 months3.4±1.6
(22)
3.3±1.3
(125)
3.4±1.2
(145)
0.81
ΔDAS28 6 months−0.6±1.4
(22)
−0.8±1.3
(125)
−0.4±1.3
(145)
0.090.09 ETA vs ADA
% Low disease activity or remission 6 m52.2%
(23)
44.3%
(131)
46.6%
(146)
0.77
% ΔDAS28≥1.231.8%
(22)
37.6% (125)26.9%
(145)
0.17
High disease activity at baselineINF
N=28
ETA
N=188
ADA
N=136
Difference between groups (p value)Post hoc comparisons between groups
DAS28 baseline6.1±0.6
(28)
6.2±0.8
(188)
6.0±0.7
(136)
0.13
DAS28 6 months4.3±1.1
(16)
4.2±1.5
(150)
4.6±1.5
(99)
0.19
ΔDAS28 6 months−1.8±1.3
(16)
−1.9±1.5
(150)
−1.4±1.6
(99)
0.050.05 ETA vs ADA
% Low disease activity or remission 6 m18.8%
(16)
24.8%
(153)
19.8%
(101)
0.60
% ΔDAS28≥1.268.8%
(16)
69.3%
(150)
48.5%
(99)
0.0030.003 ETA vs ADA
  • ADA, adalimumab; DAS28, disease activity score based on 28-joint status; ΔDAS28, DAS28 change; ETA, etanercept; INF, infliximab; TNF, tumour necrosis factor.

  • Bold typeface indicates statistical significance.